Drug candidate for weight management, with preventive and curative effects on CV and metabolic risks

• Normalisation of weight gain
• First drug acting on several components of cardiovascularand metabolic risk (metabolic syndrome) simultaneously

TECHNOLOGY

• Chemical derivatives of imidazolines and oxazolines, which selectively target the I1 imidazoline receptors
• Devoid of α2-AR activity
• Prevention of weight increase in multiple animal models
• Combined action on hypertension, insulin resistance, glucose tolerance, and lipid metabolism in several animal models
• Wide therapeutic window, no detectable toxicity at active doses in murine models

APPLICATIONS

• Overweight/obesity treatment
• Primary prevention and/or treatment of cardiovascular and metabolic risk (metabolic syndrome)

INNOVATION ADVANTAGE

• Best-in class candidate displaying higher efficacy on metabolic risk factors and lower side effects
• I1 - agonism demonstrated to be safe in large-scale clinical studies and> 15 years of postmarketing experience
• First potential metabolic treatment for metabolic syndrome reducing riskfor DDIs related to polypharmacy
• First potential monotherapy treatment, while current treatments consist of combination of 3 to 6 drugs
• Higher tolerance, better observance and lower cost expected

DEVELOPMENT STATUS

• Preclinical data package in rodents available (PK, PD, TOX)
• Study on non human primate model ongoing